A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens

Blood

Volumn 115, Issue 5, 2010, Pages 1098-1105

  Rodriguez, Roberto ^a   Nakamura, Ryotaro ^a   Palmer, Joycelynne M ^a   Parker, Pablo ^a   Shayani, Sepideh ^a   Nademanee, Auyaporn ^a   Snyder, David ^a   Pullarkat, Vinod ^a   Kogut, Neil ^a   Rosenthal, Joseph ^a   Smith, Eileen ^a   Karanes, Chatchada ^a   O'Donnell, Margaret ^a   Krishnan, Amrita Y ^a   Senitzer, David ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; ENGRAFTMENT SYNDROME; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER TOXICITY; LUNG HEMORRHAGE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEUTROPHIL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SCHOOL CHILD; SIBLING; THROMBOTIC THROMBOCYTOPENIC PURPURA; WHOLE BODY RADIATION; CHEMICALLY INDUCED DISORDER; DONOR; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; RADIATION DOSE; SURVIVAL;

ADOLESCENT; ADULT; BUSULFAN; CHILD; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MELPHALAN; MIDDLE AGED; PILOT PROJECTS; RADIATION DOSAGE; SIBLINGS; SIROLIMUS; SURVIVAL ANALYSIS; TACROLIMUS; THROMBOTIC MICROANGIOPATHIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; VIDARABINE; YOUNG ADULT;

EID: 77649224551     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-207563     Document Type: Article

References (29)

1. Sullivan KM. Graft-versus-host disease. In: Blume KG, Forman SJ, Applebaum FR, eds. Thomas' Hematopoitic Cell Transplantation (3rd ed). Oxford, United Kingdom: Blackwell Publishing; 2004:635-664.
2. Kirken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc. 2003; 35(3):S227-S230.
3. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation. 1999;67(7):1036-1042.
4. Longoria J, Roberts RF, Marboe CC, et al. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. J Thorac Cardiovasc Surg. 1999;117(4):714-718.
5. Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35(3):S193-S200.
6. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001;72(12):1924-1929.
7. Johnston L, Shizuru J, Stockerl-Goldstein K, et al. Rapamycin for treatment of chronic graft versus host disease. Biol Blood Marrow Transplant. 2005;11(1):47-55.
8. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004; 10(5):328-336.
9. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free imunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109(7):3108-3114.
10. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007;110(2):490-500.
11. Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and nonmethotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005;11(5):383-388.
12. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(7):551-557.
13. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112(12):4425-4431.
14. Furlong T, Kiem HP, Applebaum FR, et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant. 2008;14(5):531-537.
15. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
16. Shulman HM. Graft-versus-host disease. Surv Synth Pathol Res. 1984;3(3):233-234.
17. The National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Publication date August 9, 2006. http://ctep. cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed July 1, 2009.
18. Blume KG, Forman SJ, Appelbaum FR. Thomas' Hematopoietic Cell Transplantation (3rd ed). Oxford, United Kingdom: Blackwell Scientific Publications; 2004.
19. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol II: The Design and Analysis of Cohort Studies. IARC Scientific Publication No. 821987; Lyon, France: International Agency for Research in Cancer.
20. Cox DR. Regression models and life tables. J R Stat Soc. 1972;B34:187-220.
21. Fung HC, Cohen S, Rodriguez R, et al. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. Biol Blood Marrow Transplant. 2003;9(10):649-656.
22. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344(3):175-181.
23. Alyea EP, Li S, Kim AT, et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(8):920-926.
24. Wolff D, Andree H, Hilgendorf I, Casper J, Freund M, Junghanss C. Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation: timing and conditioning regimen may be crucial (letter to the editor). Biol Blood Marrow Transplant. 2008; 14(8):942-943.
25. Martin PJ, McDonald GB, Sanders JE, et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):320-327.
26. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14(4):418-425.
27. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology. 2000;60(3):143-154.
28. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology. 1996; 24(4):830-837.
29. Bramow S, Ott P, Thomsen Nielsen F, et al. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (rapamycin). Pharmacol Toxicol. 2001;89(3):133-139.